A Randomized Phase 3, Multicenter, Open-Label Study Comparing TH-302 in Combination With Doxorubicin vs. Doxorubicin Alone in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma

Trial Profile

A Randomized Phase 3, Multicenter, Open-Label Study Comparing TH-302 in Combination With Doxorubicin vs. Doxorubicin Alone in Subjects With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Evofosfamide (Primary) ; Doxorubicin
  • Indications Haemangiosarcoma; Kaposi's sarcoma; Leiomyosarcoma; Liposarcoma; Nerve sheath neoplasms; Rhabdomyosarcoma; Soft tissue sarcoma; Synovial sarcoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Threshold Pharmaceuticals
  • Most Recent Events

    • 05 Jun 2018 Results of a subgroup analysis the safety and efficacy of first-line chemotherapy with evofosfamide [TH 302] + doxorubicin in elderly patients presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jun 2017 Results of post-hoc analysis presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top